Dr. Prasad Raje joined LGM Pharma as CEO in 2018 with the goal of growing the organization to better serve our customers. With leadership experience across analytical testing laboratories, drug substance, and drug product, he has overseen LGM’s expansion from a leading API sourcing organization for global pharmaceutical companies to an end-to-end contract development and manufacturing organization featuring: a network of prequalified API manufacturers, well over 100,000-square-feet of US-based development and manufacturing facilities and equipment, and expert regulatory and analytical testing services.
Born and raised in India and educated in India and the US, Prasad’s extensive pharmaceutical career includes consulting and leadership roles at both large and small, public and private organizations. Most recently he was president, CEO, and board member of Nanotherapeutics, Inc.; senior vice president and head of the life sciences division at EAG Laboratories; vice president of development and manufacturing at Cambridge Major Laboratories (now Alcami); and President of Smithers Pharma Services and EVP and Managing Director of Smithers Viscient Laboratories. Prior to that he held several roles at AMRI Global leading to president and managing director at AMRI India.
He earned his PhD in organic chemistry at Auburn University.
Shailesh joined LGM Pharma in 2019, bringing extensive CMC, regulatory, and management experience in NDA, ANDA, and BLA submissions. He also has a proven track record in process development, formulation, analytical and bioanalytical method development, supply chain, metabolism, and other non-clinical studies. With 35+ years in the pharmaceutical industry, Shailesh makes effective use of science to drive quality, operational, and business efficiency. He has been able to rapidly create strategy into a guiding vision in a change-oriented environment.
Prior to LGM, he was VP of Pharmaceutical Development at Palatin Tech; and a manager at Ranbaxy Pharmaceuticals, and Analytical Bio-Chemistry Laboratories. Shailesh began his career as an analytical development scientist.
Ian leads LGM operations for our CDMO business. He joined LGM in 2020, having held various roles of increasing responsibility with Nexgen Pharma and its predecessor Anabolic Laboratories.
He started his career in geotechnical engineering, then became a pharmaceutical production engineer at Anabolic Labs. Throughout his Nexgen career, he served as VP Operations, overseeing three plants and a major remodel; as President, overseeing Rx sales, R&D, Quality, and Manufacturing and Packaging Operations; as Assistant CFO; and, most recently, EVP Rx Operations, overseeing 2 plants for oral solid dose and semi-solid/liquid dosage forms.
Ian earned bachelor’s and master’s degrees in civil engineering from Virginia Tech and an MBA from the University of Hawaii.
Richard joined LGM Pharma in 2019 to lead the Company’s finance organization. Richard has more than 15 years of accounting and finance experience across a variety of industries, including real estate, telecommunications, and pharmaceutical. He has led teams through finance due diligence projects (two transactions valued at approximately $750 million); relocated the accounting function of a $25 million government division as part of a cost optimization project; led multiple teams through process and internal control optimization projects (acquisitions / system conversions) and is experienced with US Securities and Exchange Commission reporting.
Previously he served as Corporate Controller at both BTI Partners and EMC (Expanding Mobile Connectivity), Assistant Controller at Maritime Telecommunications Network (MTN), and other accounting roles at BFC Financial and Broadspire.
Richard was born in the US and was raised in Venezuela, where he earned a bachelor’s degree in accounting from the University of Zulia, one of the largest universities of Venezuela.